Preview

This is your website preview.

Currently it only shows your basic business info. Start adding relevant business details such as description, images and products or services to gain your customers attention by using Boost 360 android app / iOS App / web portal.

STERISHEALTHCARE 573431969ec6680ff811d9bc Products https://www.sterisindia.com
SACUBRIGHT 200 Sacu
SACUBRIGHT 200 Sacu
COD not available
CARDIOLOGYRANGE by Sacubitril (97mg), Valsartan (103mg)

SACUBRIGHT 200

INR 518 INR 740
You Save: INR 222 (30%)

Description

Product details

SACUBRIGHT 200 Sacubitril (97mg), Valsartan (103mg) SACUBRIGHT 200 is a combination medication containing two active ingredients: Sacubitril (97mg) and Valsartan (103mg). This combination is designed to provide dual inhibition of the renin-angiotensin-aldosterone system (RAAS) for the treatment of heart failure with reduced ejection fraction (HFrEF). Sacubitril is a neprilysin inhibitor, while Valsartan is an angiotensin II receptor blocker (ARB). Together, they work synergistically to improve cardiovascular outcomes in patients with HFrEF by targeting different pathways involved in the pathophysiology of heart failure. Neprilysin is an enzyme responsible for the degradation of natriuretic peptides, which play a crucial role in regulating blood pressure and fluid balance. By inhibiting neprilysin, Sacubitril increases the levels of natriuretic peptides, leading to vasodilation, natriuresis, and diuresis, which helps reduce blood pressure, preload, and afterload on the heart. Valsartan, as an ARB, blocks the effects of angiotensin II, a vasoconstrictor and stimulator of aldosterone secretion. By antagonizing the angiotensin II type 1 (AT1) receptors, Valsartan dilates blood vessels, reduces blood pressure, and attenuates the deleterious effects of angiotensin II on cardiac remodeling and fibrosis. SACUBRIGHT 200 is indicated for the treatment of symptomatic HFrEF in patients with New York Heart Association (NYHA) class II-IV heart failure. Clinical studies have demonstrated that this combination therapy reduces the risk of cardiovascular death and hospitalization for heart failure compared to traditional therapy with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) alone. As with any medication, SACUBRIGHT 200 may cause side effects, including hypotension, hyperkalemia, renal impairment, and angioedema. Patients should be monitored regularly for these adverse effects, especially during initiation and dose titration. Overall, SACUBRIGHT 200 represents an innovative approach to the management of HFrEF, offering superior efficacy and cardiovascular benefits compared to standard therapy. However, it should only be used under the supervision of a healthcare professional experienced in the management of heart failure and in accordance with established treatment guidelines. For further information: EMAIL: info@sterispharma.com / contact@sterispharma.com CALL/WHATSAPP: 7877551268, 7849827488 Order Now https://www.sterisonline.com/product/sacubright-200-134307

Have any question or need any business consultation?

Have any question or need any business consultation?

Contact Us
Chat with us